GSK Obtains Exclusive Rights to Amicus Therapeutics’ Drug for Fabry Disease
By Editorial Team
Pharma Deals Review: Vol 2010 Issue 9 (Table of Contents)
Published: 30 Nov-2010
DOI: 10.3833/pdr.v2010.i9.1400 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
GlaxoSmithKline has licenced Amigal™, a late stage treatment for the rare disorder Fabry disease...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS